Literature DB >> 20138357

Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial.

Roman Hovorka1, Janet M Allen, Daniela Elleri, Ludovic J Chassin, Julie Harris, Dongyuan Xing, Craig Kollman, Tomas Hovorka, Anne Mette F Larsen, Marianna Nodale, Alessandra De Palma, Malgorzata E Wilinska, Carlo L Acerini, David B Dunger.   

Abstract

BACKGROUND: Closed-loop systems link continuous glucose measurements to insulin delivery. We aimed to establish whether closed-loop insulin delivery could control overnight blood glucose in young people.
METHODS: We undertook three randomised crossover studies in 19 patients aged 5-18 years with type 1 diabetes of duration 6.4 years (SD 4.0). We compared standard continuous subcutaneous insulin infusion and closed-loop delivery (n=13; APCam01); closed-loop delivery after rapidly and slowly absorbed meals (n=7; APCam02); and closed-loop delivery and standard treatment after exercise (n=10; APCam03). Allocation was by computer-generated random code. Participants were masked to plasma and sensor glucose. In APCam01, investigators were masked to plasma glucose. During closed-loop nights, glucose measurements were fed every 15 min into a control algorithm calculating rate of insulin infusion, and a nurse adjusted the insulin pump. During control nights, patients' standard pump settings were applied. Primary outcomes were time for which plasma glucose concentration was 3.91-8.00 mmol/L or 3.90 mmol/L or lower. Analysis was per protocol. This trial is registered, number ISRCTN18155883.
FINDINGS: 17 patients were studied for 33 closed-loop and 21 continuous infusion nights. Primary outcomes did not differ significantly between treatment groups in APCam01 (12 analysed; target range, median 52% [IQR 43-83] closed loop vs 39% [15-51] standard treatment, p=0.06; <or=3.90 mmol/L, 1% [0-7] vs 2% [0-41], p=0.13), APCam02 (six analysed; target range, rapidly 53% [48-57] vs slowly absorbed meal 55% [37-64], p=0.97; <or=3.90 mmol/L, 0% [0-4] vs 0% [0-0], p=0.16]), and APCam03 (nine analysed; target range 78% [60-92] closed loop vs 43% [25-65] control, p=0.0245, not significant at corrected level; <or=3.90 mmol/L, 10% [2-15] vs 6% [0-44], p=0.27). A secondary analysis of pooled data documented increased time in the target range (60% [51-88] vs 40% [18-61]; p=0.0022) and reduced time for which glucose concentrations were 3.90 mmol/L or lower (2.1% (0.0-10.0) vs 4.1% (0.0-42.0); p=0.0304). No events with plasma glucose concentration lower than 3.0 mmol/L were recorded during closed-loop delivery, compared with nine events during standard treatment.
INTERPRETATION: Closed-loop systems could reduce risk of nocturnal hypoglycaemia in children and adolescents with type 1 diabetes. FUNDING: Juvenile Diabetes Research Foundation; European Foundation for Study of Diabetes; Medical Research Council Centre for Obesity and Related Metabolic Diseases; National Institute for Health Research Cambridge Biomedical Research Centre. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138357     DOI: 10.1016/S0140-6736(09)61998-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  151 in total

1.  Development of a multi-parametric model predictive control algorithm for insulin delivery in type 1 diabetes mellitus using clinical parameters.

Authors:  M W Percival; Y Wang; B Grosman; E Dassau; H Zisser; L Jovanovič; F J Doyle
Journal:  J Process Control       Date:  2011-03-01       Impact factor: 3.666

2.  Continuous glucose monitoring considerations for the development of a closed-loop artificial pancreas system.

Authors:  D Barry Keenan; Benyamin Grosman; Harry W Clark; Anirban Roy; Stuart A Weinzimer; Rajiv V Shah; John J Mastrototaro
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

3.  AP@home: a novel European approach to bring the artificial pancreas home.

Authors:  Lutz Heinemann; Carsten Benesch; J Hans DeVries
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

4.  Postprandial glycemic excursions with the use of a closed-loop platform in subjects with type 1 diabetes: a pilot study.

Authors:  Arianne C van Bon; Jeroen Hermanides; Robin Koops; Joost B L Hoekstra; J Hans DeVries
Journal:  J Diabetes Sci Technol       Date:  2010-07-01

5.  Decade in review-paediatric endocrinology: New genes, new therapies.

Authors:  Mehul T Dattani
Journal:  Nat Rev Endocrinol       Date:  2015-09-08       Impact factor: 43.330

6.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Authors:  Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

Review 7.  Can technological solutions for diabetes replace islet cell function?

Authors:  Justin M Gregory; Daniel J Moore
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

8.  The identifiable virtual patient model: comparison of simulation and clinical closed-loop study results.

Authors:  Sami S Kanderian; Stuart A Weinzimer; Garry M Steil
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

Review 9.  Technology to optimize pediatric diabetes management and outcomes.

Authors:  Jessica T Markowitz; Kara R Harrington; Lori M B Laffel
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

10.  Evaluating the accuracy and large inaccuracy of two continuous glucose monitoring systems.

Authors:  Lalantha Leelarathna; Marianna Nodale; Janet M Allen; Daniela Elleri; Kavita Kumareswaran; Ahmad Haidar; Karen Caldwell; Malgorzata E Wilinska; Carlo L Acerini; Mark L Evans; Helen R Murphy; David B Dunger; Roman Hovorka
Journal:  Diabetes Technol Ther       Date:  2012-12-20       Impact factor: 6.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.